Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKG2D CAR-NK
- Development stage
- Phase 2
- Lead developer
- Hangzhou Cheetah Cell Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Hepatic Artery Transfusion
01
Overview
NKG2D CAR-NK is a gene-modified cell therapy being developed by Hangzhou Cheetah Cell Therapeutics for the treatment of solid tumors, including platinum-resistant recurrent epithelial ovarian cancer, colorectal cancer, and liver metastases. The therapy involves Natural Killer (NK) cells genetically engineered to express a chimeric antigen receptor (CAR) that targets ligands of the NKG2D receptor (such as MICA, MICB, and ULBPs), which are commonly upregulated on the surface of various cancer cells. By targeting these ligands, the CAR-NK cells can specifically recognize and eliminate tumor cells while potentially minimizing off-target effects on healthy tissues. The drug is currently being evaluated in Phase 1 and Phase 2 clinical trials, administered via intravenous infusion or hepatic artery transfusion.
- Other names
- NKG2D CAR-NK cellsNKG-2D CAR-NK cellsNKG 2D CAR-NK cellsNKG2D-CAR NK cellsNKG-2D-CAR NK cellsNKG 2D-CAR NK cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on NKG2D CAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKG2D CAR-NK.